New Haven, Connecticut, United States
Leading an independent research group of 25+ FTEs, funded by 20+ agencies including NIH, AACR, DoD, CRI, Damon Runyon, ACGT, BCA, MRA, TMKF, Sontag, Ludwig, VF, Pershing, Blavatnik, JDRF, LRA, PCF, St Baldrick. https://sidichenlab.org Scientific / laboratory achievements: Pioneered in vivo genome engineering methods for cancer modeling and in vivo CRISPR screening (Cell 2014, Cell 2015) Developed in vivo T cell CRISPR screens and identification of novel immunotherapy targets (Cell 2019, NBT 2019, Cell Metab 2022, Nature 2026 in press) Developed AAV-Cpf1 based CAR-T engineering and screening system (Nature Methods 2019, NBT 2023) Developed MAEGI and MUCIG as novel types of cancer immune gene therapy (Nature Immunology 2019, NBT 2025) Performed the first in vivo NK knockout screen and gain-of-function screen (NBT 2024, Nature 2026) Developed modular vaccine platforms and AI-guided targeted protein localization for vaccine design (NBE 2025, NBT 2026 in press) Industry achievements and operational leadership: Co-founded EvolveImmune Therapeutics (a startup company developing first-in-class biologics, currently at series B stage, and lead program in Phase 1) https://www.evolveimmune.com Founded Cellinfinity Bio and served on Board of Directors (a startup company developing differentiating in vivo CAR-T therapy, currently at seed stage, and lead program in Investigator-initiated trial (IIT)) https://www.cellinfinitybio.com Founded MTM and served on Board of Directors (a startup company developing highly innovative in vivo immune modulation therapy, currently at seed stage, and lead program in Investigator-initiated trial (IIT)) (Stealth model) Inventor on 5 issued patents and 45+ patent applications.
https://www.cellinfinitybio.com
http://www.sapa-ct.org
https://evolveimmune.com